## SUPPLEMENTARY TABLES

### Supplementary Table 3. The potential SIAH1-interacting proteins.

| Gene Name   | Unique peptides | Sequence coverage [%] |
|-------------|-----------------|-----------------------|
| RPS3        | 25              | 75.7                  |
| HNRNPA2B1   | 27              | 76.8                  |
| RPL7        | 23              | 70.2                  |
| HIST2H2AB   | 2               | 70                    |
| NME2        | 6               | 75                    |
| PFN1        | 13              | 78.6                  |
| NPM1        | 24              | 75.5                  |
| ENO1        | 27              | 71.2                  |
| RPLP2       | 8               | 80                    |
| NEDD8       | 7               | 81.5                  |
| HIST3H2BB   | 2               | 76.2                  |
| PRDX1       | 12              | 79.9                  |
| RPL24       | 22              | 73.2                  |
| UBA52       | 2               | 71.1                  |
| RPS27A      | 7               | 73.1                  |
| PPIA        | 17              | 85.5                  |
| HIST1H4A    | 16              | 72.8                  |
| UBE2N       | 12              | 70.4                  |
| VIM         | 36              | 72.3                  |
| PRDX6       | 17              | 72.3                  |

### Supplementary Table 4. The potential ubiquitination sites.

| Gene Name | Positions within proteins | Score  | GlyGly (K) Probabilities                                      | OE/NC     | \( P \) value (Significance A) |
|-----------|---------------------------|--------|-------------------------------------------------------------|-----------|---------------------------------|
| RPS3      | 214                       | 176.53 | KPLPDHSIVEPK(1)DEILPTTPISEQK                                 | 3.21965   | 0.00983847                      |
| RPS3      | 10                        | 106.68 | K(1)FVADGIJK                                                | 0.33357   | 0.0373192                       |
| RPS3      | 8                         | 91.626 | AVQISK(1)K(1)R                                              | 0.315526  | 0.0281246                       |
| RPS3      | 141                       | 146.79 | GCEVVVSGK(1)LR                                              | 0.284557  | 0.0161287                       |
| RPS3      | 230                       | 133.32 | G(1)PEPPAMPQPVPTA                                           | 0.916819  | 0.981948                        |
| RPS3      | 202                       | 63.894 | K(1)PLPDHSIVEPK                                             | 0.642557  | 0.45523                         |
| RPS3      | 90                        | 70.96  | FGFPEGSVELYAEK(1)VATR                                       | 0.593273  | 0.363198                        |
| RPS3      | 62                        | 147.2  | TQNVLGEK(1)GRR                                              | 0.495039  | 0.201236                        |
| RPS3      | 197                       | 100.55 | IMLPVDPTGK(0.992)IGPK(0.008)                                | 0.432506  | 0.120391                        |
| RPS3      | 75                        | 222.08 | IRELTAVVK(1)R                                               | 0.385161  | 0.0735663                       |
| RPS3      | 7                         | 97.068 | AVQISK(1)K(1)R                                              | 0.359152  | 0.0533932                       |
### Supplementary Table 5. Clinical and pathological features of EOC patients.

| Characteristics | Age (years) | Pathological type            | FIGO stage | Grade | Progression-free survival (months) |
|-----------------|-------------|-----------------------------|------------|-------|-----------------------------------|
| EOC1            | 66          | serous mucinous carcinoma   | IIIA1(i)   | Low   | >6                                |
| EOC2            | 62          | serous carcinoma            | IIIA2      | Moderate | >6                              |
| EOC3            | 70          | mucinous carcinoma          | IVA        | High   | >6                                |
| EOC4            | 65          | serous carcinoma            | IIIC       | High   | >6                                |
| EOC5            | 63          | serous mucinous carcinoma   | IIIC       | Moderate | >6                              |
| EOC6            | 64          | serous carcinoma            | IVA        | Moderate | >6                              |
| EOC7            | 68          | serous carcinoma            | IIIC       | High   | >6                                |
| EOC8            | 67          | clear cell carcinoma        | IVA        | High   | >6                                |
| EOC9            | 69          | endometrioid carcinoma      | IIIA1(ii)  | Low   | >6                                |
| EOC10           | 71          | mucinous carcinoma          | IIIC       | Moderate | >6                              |
| EOC11           | 65          | serous carcinoma            | IVA        | Low   | >6                                |
| EOC12           | 59          | serous carcinoma            | IVA        | High   | >6                                |
| EOC13           | 60          | serous carcinoma            | IIIC       | High   | >6                                |
| EOC14           | 68          | serous mucinous carcinoma   | IIIC       | Low   | <6                                |
| EOC15           | 68          | mucinous carcinoma          | IVA        | High   | <6                                |
| EOC16           | 65          | clear cell carcinoma        | IIIC       | High   | <6                                |
| EOC17           | 66          | serous carcinoma            | IIIB       | Moderate | <6                              |
| EOC18           | 69          | serous carcinoma            | IIIA2      | Moderate | <6                              |
| EOC19           | 72          | serous carcinoma            | IIIC       | High   | <6                                |
| EOC20           | 66          | serous carcinoma            | IIIB       | High   | <6                                |
| EOC21           | 70          | serous carcinoma            | IVB        | High   | <6                                |
| EOC22           | 65          | serous carcinoma            | IIIC       | Moderate | <6                              |
| EOC23           | 76          | serous carcinoma            | IIIC       | High   | <6                                |
| EOC24           | 60          | serous carcinoma            | IVA        | High   | <6                                |